EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)

Drug–Drug Interaction Assessment of WXFL10203614 With Rifampicin, Itraconazole and Metformin: A Three‐Cohort Phase I Study

Jinmei Zhou, Mengshuang Gao, Daolei Zhou, Zhiwei Zhang, Huan Zhang, Yu Sun, Huan Zhou

Clinical Pharmacology in Drug Development · 2026-11 · 15 (11)

DOI: 10.1002/cpdd.70119 ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift Clinical Pharmacology in Drug Development, online erschienen am 14.11.2026. Verfasst von Jinmei Zhou und 6 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy, Bengbu Medical University, Bengbu, Anhui, China. Hauptthemen laut MEDLINE: Metformin, Itraconazole, Rifampin, Hypoglycemic Agents. Die Arbeit nennt 30 Literaturangaben. Gefördert von: Longhu Talent Project of Bengbu Medical University, Anhui Province Jointly-Constructed Key Laboratory of Innovative Drugs Pharmaceutical Research and Clinical Evaluation, Talent Introduction Research Startup Fund of The First Affiliated Hospital of Anhui Medical University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

To evaluate the effects of rifampicin and itraconazole on the pharmacokinetics (PK) of the Janus kinase 1 (JAK1) inhibitor WXFL10203614 and the effects of steady‐state WXFL10203614 on metformin PK and safety. In this single‐center, open‐label, fixed‐sequence, self‐controlled Phase I study, 54 healthy participants were enrolled into three cohorts. Plasma and urine drug concentrations were measured using validated liquid chromatography–tandem mass spectrometry. Drug–drug interactions were assessed using geometric mean ratios and 90% confidence intervals for prespecified PK parameters. Rifampicin reduced WXFL10203614 systemic exposure by approximately 40% and shortened its elimination half‐life by 39%, whereas itraconazole increased exposure by approximately 26%. Changes in C max were less pronounced, suggesting that altered systemic clearance contributed substantially to these interactions. Steady‐state WXFL10203614 did not meaningfully alter metformin plasma exposure but reduced metformin renal clearance and cumulative urinary excretion by approximately 36% and 30%, respectively, consistent with an effect on renal tubular secretion involving MATE1/MATE2‐K. No serious adverse events occurred, and most treatment‐emergent adverse events were Grade 1. WXFL10203614 was sensitive to CYP3A induction, whereas the effect of CYP3A inhibition was modest. Concomitant use with strong CYP3A inducers should be avoided where possible. The reduced renal clearance and urinary excretion of metformin support consideration of MATE‐mediated interactions when WXFL10203614 is co‐administered with metformin or other relevant transporter substrates.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MetforminItraconazoleRifampinHypoglycemic AgentsProtein Kinase InhibitorsHumansDrug InteractionsFemaleMaleAdultYoung AdultMiddle AgedOrganic Cation Transport ProteinsHalf-LifeTandem Mass SpectrometryCohort StudiesJanus Kinase 1Healthy Volunteers

Stichwörter der Autor:innen

WXFL10203614drug–drug interactionitraconazolemetforminrifampicin

Substanzen

MetforminItraconazoleRifampinHypoglycemic AgentsOrganic Cation Transport ProteinsSLC47A1 protein, humanProtein Kinase InhibitorsJanus Kinase 1

Autor:innen und Institutionen

  • School of Pharmacy, Bengbu Medical University, Bengbu, Anhui, China.
  • Clinical Trial Center, The First Affiliated Hospital of Bengbu Medical University, Bengbu, Anhui, China.
  • College of Laboratory Medicine, Bengbu Medical University, Bengbu, Anhui, China.
  • Zhuohe Pharmaceutical Group Co., Ltd., Wuxi City, Jiangsu Province, China.

Förderung

  • Longhu Talent Project of Bengbu Medical University
  • Anhui Province Jointly-Constructed Key Laboratory of Innovative Drugs Pharmaceutical Research and Clinical Evaluation
  • Talent Introduction Research Startup Fund of The First Affiliated Hospital of Anhui Medical University

Zitieren

APA

Zhou, J., Gao, M., Zhou, D., Zhang, Z., Zhang, H., Sun, Y., & Zhou, H. (2026). Drug–Drug Interaction Assessment of WXFL10203614 With Rifampicin, Itraconazole and Metformin: A Three‐Cohort Phase I Study. Clinical Pharmacology in Drug Development, 15(11). https://doi.org/10.1002/cpdd.70119

Vancouver

Zhou J, Gao M, Zhou D, Zhang Z, Zhang H, Sun Y, et al. Drug–Drug Interaction Assessment of WXFL10203614 With Rifampicin, Itraconazole and Metformin: A Three‐Cohort Phase I Study. Clinical Pharmacology in Drug Development. 2026;15(11). doi:10.1002/cpdd.70119

BibTeX
@article{Zhou2026,
  author = {Zhou, Jinmei and Gao, Mengshuang and Zhou, Daolei and Zhang, Zhiwei and Zhang, Huan and Sun, Yu and Zhou, Huan},
  title = {Drug–Drug Interaction Assessment of WXFL10203614 With Rifampicin, Itraconazole and Metformin: A Three‐Cohort Phase I Study},
  journal = {Clinical Pharmacology in Drug Development},
  year = {2026},
  volume = {15},
  number = {11},
  doi = {10.1002/cpdd.70119}
}
Kostenlos starten →